title: [Efficacy of granisetron as anti-emetic agent for emesis induced by intra-arterial injection therapy for hepatocellular carcinoma].
abstract: The effect of granisetron in preventing nausea and emesis induced by intraarterial chemotherapy was comparatively studied with a historical control group (46 cases) in 50 patients with hepatocellular carcinoma receiving intraarterial anti-tumor drugs such as cisplatin and doxorubicin. Emesis was perfectly controlled in 39 out of 50 patients in the treatment group (78%), in comparison to 33 out of 46 patients (71.7%) in the historical control group. This represented no statistical significance between the two groups. In terms of the severity of nausea, however, the granisetron group demonstrated significant superiority to the control group with 27 out of 50 patients (54%) being free of symptoms compared with 16 out of 46 patients (34.8%) in the control group. A stratified analysis of the data also demonstrated significant superiority of the granisetron group over the historical group in the number of emetic episodes and the severity of nausea in female patients, who are more predisposed to emesis. The above results confirm the usefulness of granisetron as an antiemetic agent used for the prevention of acute nausea and emesis induced by intraarterial chemotherapy.
authors.affiliation: Third Dept. of Internal Medicine, Niigata University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Ichida
authors.forename: O
authors.initials: O
authors.lastname: Isokawa
authors.forename: S
authors.initials: S
authors.lastname: Itoh
authors.forename: H
authors.initials: H
authors.lastname: Ohta
authors.forename: K
authors.initials: K
authors.lastname: Takagi
authors.forename: S
authors.initials: S
authors.lastname: Hatakeyama
authors.forename: T
authors.initials: T
authors.lastname: Tsuruya
authors.forename: Y
authors.initials: Y
authors.lastname: Doya
authors.forename: A
authors.initials: A
authors.lastname: Nozawa
authors.forename: K
authors.initials: K
authors.lastname: Hata
authors.forename: H
authors.initials: H
authors.lastname: Hara
authors.forename: S
authors.initials: S
authors.lastname: Hirose
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Asakura
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D017829:Granisetron / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D002945:Cisplatin; D004317:Doxorubicin; D017829:Granisetron